Business Context and Reporting Period
Company: LifeMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 11, 2022
Event: Entry into a Material Definitive Agreement to acquire Cleared Technologies, PBC ("Cleared").
Cleared is a privately held telehealth company based in New York City providing personalized treatments for allergy, asthma, and immunology. The Company expects the acquisition to close in the first quarter of 2022.
Key Financial Metrics and Transaction Terms
This filing details a specific acquisition agreement rather than periodic financial performance. Key transaction metrics include:
- Base Acquisition Consideration: $3,920,000 total, structured as:
- $460,000 payable at closing.
- $1,730,000 payable within one year of closing.
- $1,730,000 payable within two years of closing.
- Earn-Out Consideration: Up to $72,800,000 contingent on Cleared achieving $150,000,000 in revenue within a trailing twelve-month period by December 31, 2025.
- Payment Method: The Company may pay in cash, common stock (valued based on a 20-day VWAP), or a combination thereof, at its sole discretion.
- Escrow: A portion of the consideration will be held in escrow at closing for indemnification claims and post-closing adjustments.
Note: This filing does not provide LifeMD's current revenue, profit, cash flow, margins, debt, or liquidity figures. Investors should refer to the most recent Form 10-K or 10-Q for those metrics.
Material Changes and Outlook
Material Change: The Company has entered a definitive agreement to expand its telehealth capabilities through the acquisition of Cleared. This represents a strategic shift to include allergy, asthma, and immunology treatments.
Outlook and Conditions:
- Closing Conditions: The transaction is subject to customary conditions, including the absence of governmental orders restraining the deal, accuracy of representations, and no material adverse effect on either party.
- Termination Rights: The agreement is terminable by either party if closing conditions are not satisfied by January 31, 2022, or in the event of uncured material breaches.
- Forward-Looking Risks: Management notes risks regarding the failure to satisfy closing conditions, regulatory approvals, and the inherent uncertainty of the earn-out milestones.
Investor Verification Checklist
- Verify the final closing date and whether the transaction closed in Q1 2022 as expected.
- Confirm the mix of cash versus stock used for the initial $3.92 million payment and any subsequent earn-out payments.
- Monitor Cleared's revenue performance against the $150 million threshold required to trigger the $72.8 million earn-out.
- Review the Company's latest 10-K or 10-Q to assess current liquidity and ability to fund the cash portion of the deal.
- Check for any regulatory approvals or governmental orders that may have impacted the closing conditions.